Advanced hepatic carcinoma
Conditions
Interventions
Group 1:Sorafenib treatment
Group 2:Camrelizumab treatment
Group 3:Sorafenib combined with Camrelizumab treatment
Sponsors
Lanzhou University Second Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) According to clinical symptoms, signs and related imaging, pathological examination, and positive AFP, patients with a clear diagnosis of HCC (refer to Hepatobiliary Cancers NCCN Clinical Practice Guideline in Oncology, Version 4.2017); (2) Aged 18 to 70 years old, life expectancy >=12 weeks; (3) According to the Solid Tumor Response Assessment Criteria (RECIST), there is at least one tumor lesion (no local treatment), and the target lesion has not received local treatment; (4) The lesion is >5mmx5mmx5mm; (5) those who have received topical treatment, such as surgery, radiofrequency ablation, hepatic artery embolization, chemotherapy, radiotherapy, percutaneous puncture or cryoablation, but the target lesion volume increased by more than 25% and stopped for more than 4 weeks; (6) with or without extrahepatic metastases; (7) The Eastern Cancer Cooperative Group (ECOG) score =60x10^9/L; hemoglobin >=85 g/L; prothrombin time international normalized ratio INR =28g/L; total bilirubin <=51.3umol/L; alanine transferase and aspartate transferase <=5 ULN; (11) Renal function: blood creatinine <=1.5 ULN.
Exclusion criteria
Exclusion criteria: (1) Previous systemic treatment (including novel molecular targeted therapy); (2) There are serious infections in the clinic; (3) Patients suspected of drug allergy and serious adverse reactions; (4) Patients who are concurrently unable to assess the efficacy of other serious disease researchers; (5) Those who are in critical condition and need to live in the ICU; (6) Patients with renal insufficiency, who may have pregnancy in March before and after the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-free survival;Overall survival;Disease control rate;Objective response rate; | — |
Countries
China
Contacts
Public ContactWang Chen
Lanzhou University Second Hospital
Outcome results
None listed